TE671 rhabdomyosarcoma, T98G glioblastoma, MDA-MB-468 breast cancer, and NCI-H1299 larynx cancer cells showed the best response to MGN treatment (Table 2) [1], and thus they were further used to explore a possible underlying MGN-mediated mechanism of anti-cancer action on the cellular level. This evidence concerns the gene HELT and laryngeal neoplasm.